Noritate

Pouchitis, Liver Abscess, Amebic, Lung Abscess + 53 more

Treatment

41 FDA approvals

20 Active Studies for Noritate

What is Noritate

Metronidazole

The Generic name of this drug

Treatment Summary

Metronidazole is an antibiotic used to treat a variety of bacterial, parasitic, and fungal infections. It is most commonly used for gastrointestinal infections, but can also be used to treat trichomoniasis, giardiasis, and amebiasis. Metronidazole has been available since the 1970s and comes in capsule, tablet, topical, and suppository forms.

Flagyl

is the brand name

image of different drug pills on a surface

Noritate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Flagyl

Metronidazole

1963

449

Approved as Treatment by the FDA

Metronidazole, commonly known as Flagyl, is approved by the FDA for 41 uses including Abscess and Bone and Joint Infections .

Abscess

Bone and Joint Infections

Liver Abscess

Communicable Diseases

Osteomyelitis

Bacterial Endocarditis

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Bismuth subsalicylate

Abdominal Abscess

Abdominal Infection

Skin and skin structure infections

Gynaecological infection

Lung Abscess

Endometritis

Central Nervous System Bacterial Infections

Bacterial Meningitis

Pneumonia

intra-abdominal bacterial infections

hepatic abscess

Tubo-ovarian abscess

Lung Abscess

Curling Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Lower respiratory tract infection bacterial

Bacterial Septicemia

Bacteria, Anaerobic

Bacterial Infections

Duodenal Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Meningitis

Abscess, Intra-Abdominal

Empyema

asymptomatic Trichomoniasis

Exposure via partner

Endomyometritis

Bacterial Peritonitis

Central Nervous System Bacterial Infections

Empyema

Trichomonas Infections

Endometritis

Endometritis

Bacteria

Endocarditis, Bacterial

Communicable Diseases

Effectiveness

How Noritate Affects Patients

Metronidazole is an antibiotic used to treat certain bacterial and protozoal infections such as amebiasis, trichomoniasis, and giardiasis. It is effective against some types of anaerobic bacteria, but not against facultative anaerobes or obligate aerobes. Metronidazole works by causing DNA damage to the microbes it targets. It is important to be aware of the risks of taking metronidazole, including peripheral neuropathy, convulsions, and possible carcinogenicity in mice and rats. If convulsions or numbness occur, discontinue

How Noritate works in the body

Metronidazole works by entering cells and then blocking the production of proteins and DNA. This only works on anaerobic bacteria and protozoa, which have an electron-transport system that helps reduce the nitro group of metronidazole into nitro radicals. This reaction produces toxic metabolites that damage the DNA and proteins of the organism, leading to its death.

When to interrupt dosage

The suggested measure of Noritate is based on the identified ailment, including Exposure via partner, Skin and Curling Ulcer. The dosage amount fluctuates, contingent upon the technique of delivery (e.g. Capsule or Vaginal) noted in the table below.

Condition

Dosage

Administration

Bacterial Vaginosis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Bacterial Septicemia

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Bacterial Peritonitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Tubo-ovarian abscess

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Trichomonas Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

post-surgical vaginal cuff infection

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Inflammatory Papule

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Pouchitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Giardiasis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Vulvovaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Uterine Cervicitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Exposure via partner

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Candida albicans

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Bacterial Meningitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Sinusitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Endocarditis, Bacterial

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Operative Surgical Procedures

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Lockjaw

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Cream - Vaginal, Suppository - Vaginal, Suppository, Suppository - Rectal, Rectal, Injection - Intravenous, Kit, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, extended release - Oral, Tablet, extended release, Tablet, coated, Tablet, coated - Oral

Warnings

Noritate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

Pregnancy Trimester, First

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

There are 20 known major drug interactions with Noritate.

Common Noritate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Metronidazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Metronidazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Metronidazole.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Metronidazole.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Metronidazole.

Noritate Toxicity & Overdose Risk

The toxic dose of metronidazole in rats is 5000mg/kg. Taking too much of the drug can lead to nerve damage, confusion, seizures, a bad reaction if taken with alcohol, dark urine, a bad taste in the mouth, nausea, stomach discomfort, and dizziness. There is no specific antidote for an overdose, so medical treatment should be administered to help remove the drug from the body. Contacting the poison control center for more information is also advised.

image of a doctor in a lab doing drug, clinical research

Noritate Novel Uses: Which Conditions Have a Clinical Trial Featuring Noritate?

Currently, 179 active clinical trials are being conducted to assess the potential of Noritate in alleviating Curling Ulcer, Periodontitis and Central Nervous System Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Lockjaw

0 Actively Recruiting

Uterine Cervical Erosion

0 Actively Recruiting

Gum Disease

3 Actively Recruiting

Phase 3, Not Applicable

Abdominal Infection

0 Actively Recruiting

Rosacea

0 Actively Recruiting

Balantidiasis

0 Actively Recruiting

Empyema

1 Actively Recruiting

Phase 4

Abdominal Abscess

2 Actively Recruiting

Phase 4, Phase 1, Phase 2

Bacteria

0 Actively Recruiting

Trichomonas Infections

0 Actively Recruiting

Vulvovaginitis

0 Actively Recruiting

Lung Abscess

0 Actively Recruiting

Pouchitis

5 Actively Recruiting

Phase 2, Phase 3, Early Phase 1, Phase 4

Atopic Dermatitis

12 Actively Recruiting

Phase 2, Phase 3, Phase 4, Not Applicable

Acne Vulgaris

0 Actively Recruiting

Operative Surgical Procedures

0 Actively Recruiting

Liver Abscess, Amebic

0 Actively Recruiting

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Amebic colitis

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Noritate Reviews: What are patients saying about Noritate?

5

Patient Review

9/16/2012

Noritate for Acne Rosacea

This cream was gentle but effective on my rosacea. It cleared up within a week and I didn't need to use it for months afterwards; the effects were really long lasting.

5

Patient Review

1/21/2011

Noritate for Acne Rosacea

I've been using this treatment for a couple years and it's done wonders for my skin. At first, I used it as recommended twice daily; however, that left my skin feeling very dry and slightly irritated. Once I started only using it once per day (as suggested by my doctor), though, things improved dramatically.

5

Patient Review

10/17/2010

Noritate for Acne Rosacea

I have very sensitive skin and had reactions to every other treatment the doctor tried. This one is much more effective in controlling both the redness and breakouts, but it takes a little bit of time to work its magic.

5

Patient Review

1/21/2014

Noritate for Acne Rosacea

I had really intense burning and itching sensations all over my face for months before I went to a doctor. They prescribed me Noritate and the symptoms subsided within days. It's been five years now and I only have to use it occasionally when my symptoms flare up again.

5

Patient Review

10/12/2017

Noritate for Acne Rosacea

Noritate has been an absolute godsend in managing my Rosacea. It's definitely on the pricier side, but it is worth every penny to me.

5

Patient Review

1/1/2008

Noritate for Acne Rosacea

4.7

Patient Review

7/20/2009

Noritate for Acne Rosacea

I'm in my mid-50s and started seeing acne flareups, which I never experienced as a teenager. After being diagnosed with roseacea, my dermatologist prescribed me Noritate cream. Within a month or so, there was noticeable improvement and now the redness is gone and pimples are history.

4.3

Patient Review

8/20/2014

Noritate for Acne Rosacea

I have rosacea and this cream really helps to clear it up quickly. The only downside is that it's quite expensive.

4.3

Patient Review

1/7/2009

Noritate for Acne Rosacea

3.3

Patient Review

10/11/2009

Noritate for Acne Rosacea

I have very sensitive skin, so I was elated to find a medication that didn't aggravate my condition. Noritate has helped me noticeably in the six months I've been using it; here's hoping for even better results in the future!

2.7

Patient Review

5/25/2019

Noritate for Acne Rosacea

I was prescribed Noritate a few months ago in an effort to address my mild-to-moderate rosacea. I used it as directed, but unfortunately saw no change whatsoever. This didn't work for me at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about noritate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can Noritate cause acne?

"Most of the negative reactions were mild to moderate. Two people who were given Noritate once daily quit taking it because of bad reactions: one because their comedonal acne got worse, and one because their rosacea got worse."

Answered by AI

What is Noritate cream used for?

"This medication is designed to treat rosacea, a type of adult acne, by reducing the redness, swelling, and number of pimples on the skin."

Answered by AI

What is the generic for Noritate?

"·

There is no therapeutic equivalent to Noritate in the United States. There may be counterfeit versions of Noritate being sold online by illegal pharmacies. These medications could be dangerous and ineffective."

Answered by AI

Is Noritate the same as MetroGel?

"Both MetroGel and Noritate are topical antibiotics used to treat skin lesions caused by rosacea."

Answered by AI

Clinical Trials for Noritate

Image of ALS Global in Irving, United States.

GX-03 for Eczema

18 - 70
All Sexes
Irving, TX

This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), and the Peak Pruritus Numeric Rating Scale (PP-NRS). Safety will be evaluated through monitoring of treatment-emergent adverse events throughout the study period.

Phase 2
Recruiting

ALS Global

Turn Therapeutics

Image of Seeding Labs INC in Austin, United States.

Tailored Recommendations for Infant Gut Microbiome

No minimum age - 3
All Sexes
Austin, TX

The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.

Waitlist Available
Has No Placebo

Seeding Labs INC

Qian Yuan, MD

Seeding, Inc DBA Tiny Health

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Noritate clinical trials?

We made a collection of clinical trials featuring Noritate, we think they might fit your search criteria.
Go to Trials
Image of UNC Chapel Hill in Chapel Hill, United States.

Intrapleural Enzyme Therapy for Pleural Infection

18+
All Sexes
Chapel Hill, NC

The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection. The investigators are trying to learn: * Does using the medicine once a day work just as well as using it twice a day? * Are there any differences in outcomes between patients who get the medicine once a day versus twice a day? * Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given? Participants will: * Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung. * Be asked to give permission to join the study. * Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.

Phase 4
Waitlist Available

UNC Chapel Hill

Jason Akulian, MD, MPH

Have you considered Noritate clinical trials?

We made a collection of clinical trials featuring Noritate, we think they might fit your search criteria.
Go to Trials
Image of Office of Dental Health, Department of Health and Senior Services in Jefferson City, United States.

Dental Care for Pneumonia Prevention

60 - 100
All Sexes
Jefferson City, MO

The goal of this study is to learn if dental infection control treatment delivered to older adult nursing home residents at their place of residence will result in : * improved dental health * reduced risk of pneumonia * better glucose control for diabetic patients compared to the pre-project dental and general health evaluations of residents and the pre-project facility incidence of pneumonia. Dental infection control treatment includes treating gum infections, stopping or slowing decay with fluoride, and assisting residents with effective tooth brushing and denture cleaning daily. Previous studies indicate dental infections can be inhaled and cause pneumonia or make diabetes worse. A shortage of dentists has limited care for nursing home residents. This project will allow dental hygienists and specially trained dental assistants to treat nursing home residents using telehealth methods (computers, cameras, internet, and telephone) to talk and work with dentists in different locations.

Recruiting
Has No Placebo

Office of Dental Health, Department of Health and Senior Services

Have you considered Noritate clinical trials?

We made a collection of clinical trials featuring Noritate, we think they might fit your search criteria.
Go to Trials